UCLA presents the progress of radiotherapy at Astro 2025

UCLA presents the progress of radiotherapy at Astro 2025

Doctors and scientists from UCLA Health Jonsson Comprehensive Cancer Center will share the latest results of clinical research and research at the annual American Society for Radiation for Radiation Oncology (Astro), including research on targeted radiotherapy for recurrent prostate cancer, new approaches to stereotactic body radiation for prostate head and neck cancer, progress in MRIR and 5DCT-butided in the case of innovation and innovation in the field of innovation and innovation in the field of innovation and innovation in the field of drug and innovation and innovation. Cancer education.

At this year’s Dr. Amar Kishan, Vice President of the Executive oncology of Radiotherapy at UCLA and co -director of molecular cancer, nanotechnology and terraranostics in UCLA Health Jonson Comprehensive Cancer Center, as a leted radio -cancer center as a treatment, Ablative radiation therapy in men with recurrent prostate cancer. The results will be emphasized during the oral presentation on Sunday, September 28 at 13:10 PDT in the ballroom in San Francisco and is part of the Astro News briefings on Monday, September 29 at 11:00 PDT.

In addition, Dr. Drew Moghanaki, the head of the chest oncology in the UCLA radiotherapy department, was appointed Astro scholarship in 2025. Recognition is granted annually to doctors, physicians and scientists in honor of their unique achievements and permanent contribution to society, cancer research, education, patient care and the field of radiation oncology, emphasizing work that conducts a key role of radiation therapy in the treatment of cancer.

UCLA studies at this year’s ASTRO meeting offer exciting new information on emerging radiotherapy and imaging technology therapy, indicating innovative approaches to the treatment of safer, more precise and more effective cancer. These presentations emphasize the joint efforts of our doctors, scientists and interns and reflect long -term leadership and UCLA involvement in the development of caring for cancer. “

Dr. Michael Steinberg, professor and chairman of Radiation Oncology at David Geffen School of Medicine at UCLA and director of the Clinic at UCLA Health Jonsson Comprehensive Cancer Center

The most important information about the noteworthy presentations of the UCLA Faculty in Astro includes:

SUMMARY 148: Four years of research results of Scimitar testing stereotactic body radiotherapy after prostate surgery

Dr Jesus Juarez Casillas, co -chairman in the Department of Oncology of Radiotherapy in UCLA, will present the findings of the clinical examination of the Scimitar Phase II phase, which assessed the stereotactic radiotherapy of the body (SBT) in men threatened with prostate cancer after surgery. After four years, 62% of patients had no signs of cancer returning, local relapses were rare, and the results were favorably compared with conventional radiation approaches. Research conducted by Kishan will be presented on Sunday, September 28 at 17:05 PDT in room 24.

Summary 253: 5DCT ensures more detailed imaging of the lung tumor in patients with irregular breathing

Dr Daniel Low, professor and vice president for medical physics and innovation research in the Department of Oncology of Radiotherapy in UCLA, will report the results of the first large 5DCT study, the new CT imaging technique designed to improve scans for patients with pulmonary tumors who breathe irregularly. Unlike conventional 4DCT, which can create unbelievable images, 5DCT is responsible for breathing movement in three dimensions, as well as the speed and depth of each breath, producing clearer images without artifact. In the study of 108 5DCT patients allowed clinicians to define tumor and movement more accurately, supporting better radiation planning. The flow of work was reliable for almost all patients, even those with very variable breathing patterns, and is currently used to develop automated imaging processes such as CT 5D cone. The results will be presented on Monday, September 29 at 15:10 PDT in room 155/157.

Summary 1005: Comparison of acute side effects of the prostate under MRI control with adaptive dose painting and without

Dr. Travis Courtney, a co -chairman in the Department of Oncology of Radiotherapy in UCLA, presents studies comparing two forms of targeted prostate radiation. In the study, it concerned standard stereotactic body radiotherapy under the control of MRI (MRGSBRT) in comparison with the adaptive approach “painted in a dose”, which increases radiation to the dominant areas of cancer, while lowering the dose to the surrounding tissue. The results have shown that patients receiving adaptive dose therapy experienced higher acute side effects measured by doctors, especially urinary symptoms and intestines. However, the patient’s quality of life results were similar between two groups. Discoveries suggest that increasing the dose to specific areas of cancer may not reduce side effects and emphasize the need for further tests, because the examination is still saved by patients. The works carried out by Kishan will be presented on Monday, September 29 at 8:30 PDT in room 307/308.

Summary 1003: Analysis of sexual function after MRI-shared by MRI SBRT prostate in the Mirage study

Dr Jonathan Massachi, a resident of Oncology Radiation in Ucla, will discuss the arrangements from the Mirage study that analyzed the sexual function in men who receive SBRT for prostate cancer, comparing the standard SBT launched by CT with SBT directed by MRI. Despite the use of MRI tips to reduce the exposure to radiation to key nerves and blood vessels, almost a third of men in both groups experienced a significant decrease in sexual function two years after treatment. Factors such as hormone therapy, pelvic radiation and the initial sexual function were associated with these changes. Discoveries suggest that although SBRT under MRI control can reduce exposure to radiation, additional strategies may be needed, such as ship saving techniques to better maintain sexual functions in men undergoing prostate cancer treatment. The study conducted by Kishan will be presented on Monday, September 29 at 8:20 PDT in room 307/308.

SUMMARY 2785: Postoperative stereotactic body radiotherapy shows the promise of head and neck cancer

Dr. Miriam Lane, a resident of radiation oncology in UCLA, will present the results of research assessing postoperative SBRT in patients with newly diagnosed or recurrent head and neck cancer. The study showed that SBRT was well tolerated, without severe acute side effects and only two late serious toxicity, although about half of the patients experienced recurrence of cancer in two years. The results were similar in the case of newly diagnosed and repetitive cases. The study, conducted by Dr. Ricky Savjani, a radiation oncology assistant professor at David Geffen School of Medicine in Ucla, suggests that the postoperative SBRT is a feasible, shorter treatment option, while further research is necessary to optimize patients’ choice and improvement of results. The research will be presented on Monday, September 29 at 10:45 PDT in Hall F.

Summary 139: The examination identifies the genetic factors of prostate cancer resistant to radiation

Dr. Beth Neilsen, a former resident of Oncology Radiation in Ucla, will discuss the results of the research in which tumors from patients with prostate cancer were analyzed, which returned after radiation therapy. Studies, conducted by Kishan, have shown that these recurrent tumors have a higher frequency of mutations in genes associated with an aggressive disease and defective DNA repair, including BRCA1, BRCA2, RAD51B and polq. In comparison with untreated cancers for treatment, they also showed more aggressive molecular subtypes, higher genome risk results and reduced androgen receptor activity. These observations shed light on why some prostate cancers are resistant to radiation and can help in conducting future approaches to treatment. The discoveries will be presented on Sunday, September 28 at 15:30 PDT in room 155/157.

EDD 29 session: Strengthening patients through innovation: increasing cancer education with digital tools

Dr Trdy Wu, an oncology assistant professor at UCLA, will moderate a panel examining how digital tools transform cancer education. Panelists Dr. David Grow, Dr. Hyunsoo, and a patient supporter Jill Feldman will share strategies for creating complex cancer information, such as treatment options, side effects and forecasts, more understandable and available. The session emphasizes told animations, educational films and resources focused on a patient to reduce fear, improve understanding and support better decision making for patients moving in cancer diagnosis. The session takes place on Monday, September 29 at 17:00 PDT in room 152.

Leave a Reply

Your email address will not be published. Required fields are marked *